AVROBIO, Inc., a leader in lentiviral-based gene therapies, is a clinical stage company developing disruptive therapies that have the potential to transform patients’ lives in a single dose.

Stock Quote

Press Releases
August 29, 2019
AVROBIO, Inc. to Present at Upcoming Investor Conferences
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 29, 2019-- AVROBIO, Inc . (NASDAQ:AVRO) a Phase 2 clinical-stage gene therapy company, today announced that members of its senior management team are scheduled to participate in five upcoming investor conferences.